Navigation Links
Optimizing the Direct Amplification of Missing cDNA 5' Ends,,, Using the Eppendorf Mastercycler gradient

Fig. 3 A. Diagram of the isoamylase cDNA clone. The PCR-amplified 5' end consists of an overlapping sequence and an additional 5' area which completes the open reading frame. B. At the 5' end, the GC content of the isoamylase sequence is up to 80%, whereas the average GC content of the overall sequence is merely 52%.

Discussion

With the aid of a simple PCR reaction, it was possible to amplify the 5' end of a cDNA coding for isoamylase directly from a ?ZAPII library. Conventional plaque screening of the same cDNA library produced several short isoamylase cDNAs, but no clone with a complete coding region. This finding may be attributable to the extremely high GC content of the 5' region of the isoamylase cDNA (Fig. 3b). In regions with high GC content, RNA is able to form stable secondary structures, which abort the cDNA synthesis and lead to shorter cDNA clones. Similarly, single-stranded DNA templates in a PCR reaction can form secondary structures that may interfere with amplification [3,4]. The higher the annealing temperature selected for the PCR reaction, the more likely secondary structures will be suppressed. This may explain why annealing temperatures of 69C or even 72C lead to more specific product than a temperature of 63C, although 63C is much closer to the theoretically optimal temperature of 61C. Determining a suitable stringent annealing temperature is crucial for obtaining specific products in the PCR. In this case, temperature gradients such as those on Mastercycler gradient enable systematic, time-saving experiments.


'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
2. Optimizing pfuturbo DNA Polymerase Amplification Reactions with Perfect Match PCR Enhancer
3. Optimizing electroporation parameters
4. Optimizing Büchi® Rotary Evaporator Applications
5. Optimizing electroporation parameters
6. Optimizing Büchi® Rotary Evaporator Applications
7. Optimizing Bchi Rotary Evaporator Applications
8. Optimizing electroporation parameters
9. Optimizing electroporation parameters
10. Optimizing electroporation parameters
11. Optimizing electroporation parameters

Post Your Comments:
(Date:11/9/2009)..., SAN DIEGO, Nov. 9 NexBio, Inc....9 annual American College of Allergy, Asthma, and ...s entitled "DAS181 (Fludase®), a Sialidase, D...lammatory Effects in Animal Models of Asthma". ,...broad spectrum host-targeting drug candidate being...
(Date:11/9/2009)... Product release is a resea...ubjects, research facilities and research safety s...n. , Cedar Knolls, NJ (PR...nounced today that it has unveiled Pristima™...r research facilities that track the use and care ...
(Date:11/8/2009)...,, MOUNTAIN VIEW, Calif. Nov. 5, 2009 Comple...ncing company, today announced publication of a re...ietary DNA sequencing platform, including analysis...s. The consumables cost for these three genomes se...arrays ranged from $8,005 for 87x coverage to $1,7...
(Date:11/6/2009)..., LYNBROOK, N.Y., Nov. 6 /PRNewswire-FirstCall/ ...), a biopharmaceutical company developing first-in... its financial results for the third quarter ended...py that, in September of this year, the FDA,s Arth...by a vote of 12-0, the approval of XIAFLEX(TM) for...
Breaking Biology Technology:NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 2NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 3Xybion Unveils Pristima™ VM, an Integrated Enterprise Software Solution for Vivarium and Veterinary Care Management 2Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6
...auna Kea Technologies and VisualSonics today annou...ion agreement through which VisualSonics will mark...imaging systems to pre-clinical researchers on a w...rs with a new way to understand physiological phen...itu in animal subjects. For the first time, pre-cl...
...Nasdaq: IDMI ) today reported financial results ...r 31, 2008. Financial information presented repre... and its subsidiary, IDM Pharma S.A. , , Total re... $0.3 million, and net loss was $1.8 million or $0... the year ended December 31, 2008 were $3.1 millio...
...SHP,NASDAQ: SHPGY ), the global specialty biopha...n agreement with GlaxoSmithKline plc (NYSE: GSK ...sules CII with the aim of,improving recognition an...eement covers the United States and will more than...es effort for VYVANSE by adding over 600 sales,rep...
Other Biology Technology:VisualSonics to Sell Mauna Kea Technologies' Cellvizio(R) LAB on a Worldwide Basis to Animal Imaging Market 2VisualSonics to Sell Mauna Kea Technologies' Cellvizio(R) LAB on a Worldwide Basis to Animal Imaging Market 3IDM Pharma Reports 2008 Financial Results 2IDM Pharma Reports 2008 Financial Results 3IDM Pharma Reports 2008 Financial Results 4IDM Pharma Reports 2008 Financial Results 5IDM Pharma Reports 2008 Financial Results 6IDM Pharma Reports 2008 Financial Results 7IDM Pharma Reports 2008 Financial Results 8Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 2Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 3Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 4Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 5Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 6
(Date:11/4/2009)...tural science) , United States Using Less Wate...ay than it did 35 years ago, despite a 30 percent ...tly attributable to alternative cooling methods at...s. According to the latest USGS water use report, ... goes to cooling thermoelectric power plants. Irri...
(Date:11/4/2009)...teria, it turns out, hold the power to help milita... world clean up toxic waste on test sites. , Com... invented back in World War II and have been used ...rgy compounds are often used to propel tank shells... But with increased knowledge of their environmen...
(Date:11/4/2009)...., Oct. 19 Spectros, developer and...aging devices which shed light on life-threatening...usive distribution deals for both its T-Stat®...ered include Australia, New Zealand, The Netherla...y, France, Spain, Portugal, Poland, Greece, Turkey...
Breaking Biology News(10 mins):USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7Genomic research will enable greener cleanup of military explosive test sites 2Spectros Signs New International Distribution Deals 2VIVUS Announces Promotion of Peter Tam to President 5941 1VIVUS Announces Promotion of Peter Tam to President 5941 2VIVUS Announces Promotion of Peter Tam to President 5941 3MarketsandMarkets 3A Global Stem Cell and Advanced Technologies Market Worth US 24 88 3 Billion By 2014 14699 1MarketsandMarkets 3A Global Stem Cell and Advanced Technologies Market Worth US 24 88 3 Billion By 2014 14699 2MarketsandMarkets 3A Global Stem Cell and Advanced Technologies Market Worth US 24 88 3 Billion By 2014 14699 3Hearing Planet Publishes Hearing Aid Buyers 26apos 3B Guide 60589 1Hearing Planet Publishes Hearing Aid Buyers 26apos 3B Guide 60589 2
...the University of Michigan Medical School have dis...arly-onset form of kidney disease and renal failur...d phospholipase C epsilon or PLCE1. , Identifying ... PLCE1 affects the development of podocytes ?speci...s ability to remove waste products from blood, whi...
... the Université de Montréal has concluded that peo...r a night of studying will strongly hurt their rec...he current issue of Neuropsychopharmacology was co...f Psychology at the Université de Montréal. Dr. Ca...ital du Sacré-Coeur de Montréal. , "We already kn...
...al studies of the interactions between oscillating...the toughest questions in ecology, including the n...ing to an article in the December 2006 issue of Bi...niversity of Michigan, shows how extensions of est... populations oscillate in synchrony because of int...
Other Biology News:Mutant gene causes severe kidney disease in infants 2Mutant gene causes severe kidney disease in infants 3Mutant gene causes severe kidney disease in infants 4Negative effects of caffeine are stronger on daytime sleep than on nocturnal sleep 2
Expansion and Cryopreservation of Cells from Meridian Life Science, Inc.
HandyStep manual repeating pipette from BrandTech Scientific
Zymo-Spin I-96 from Zymo Research
RT-PCR Grade Water from Ambion
Biology Products: